No description available.

Arteriosklerose mit ihren Folgeerkrankungen ist weltweit die Erkrankung mit der höchsten Mortalität und einer hohen Morbidität. Chronische Inflammationsprozesse spielen eine zentrale Rolle in der Atherogenese. Akutphaseproteinen, insbesondere dem C-reaktiven Protein (CRP) kommen als Marker chronischer Inflammationsprozesse in der Prädiktion kardiovaskulärer Ereignisse eine besondere Bedeutung zu. Erhöhte CRP-Spiegel wurden in zahlreichen Studien als Risikofaktor für Arteriosklerose und ihre Folgeerkrankungen identifiziert. Inzwischen gibt es auch einige Hinweise, die eine Rolle von CRP über die Rolle als passiver Indikator hinaus als aktiven Teilnehmer in der Arteriosklerose aufzeigen. Oxidiertes LDL ist ebenso als Risikofaktor anerkannt, die Aufnahme in Endothelzellen ist ein wichtiger Teilschritt in der Pathogenese der Arteriosklerose. Acetyliertes LDL (acLDL) wurde als Modell für oxLDL gewählt. Wir konnten nun in der FACS-Analyse zeigen dass, sich die verschiedenen Konfigurationen von CRP, monomeres CRP (mCRP) und pentameres CRP(nCRP) in der Beeinflussung der Aufnahme von acLDL in Endothelzellen unterscheiden. M-CRP führt zur Erniedrigung der Aufnahme, nCRP nicht. Dies bestätigte sich auch in der Immunfluoreszenzfärbung, die auch eine deutlichen Abnahme der acLDLAufnahme unter Einfluss von mCRP in den Endothelzellen zeigte, nCRP bewirkte dies nach 1 und 8 Stunden Inkubation nicht. Es konnte hier also gezeigt werden, dass sich die beiden CRP-Konfigurationen in der Beeinflussung des oxLDL-Metabolismus unterscheiden. Um diesen Effekt näher zu charakterisieren, untersuchten wir die Rolle der mutmaßlichen CRP-Rezeptoren auf Endothelzellen, CD16 und CD32. Sie konnten in Endothelzellen nicht nachgewiesen werden und Antikörper gegen CD16 und CD32 hatten keinen Einfluss auf die LDL-Aufnahme in Endothelzellen. Wir konnten so zeigen, dass CD16 und CD32 (mit den Isoformen a,b und c), die als Rezeptoren für mCRP und nCRP gesehen werden, nicht exprimiert wurden und so nicht an den inhibitorischen Effekten von mCRP auf die acLDLAufnahme beteiligt sind. Wir schlagen daher vor, dass andere Rezeptoren und/oder nichtrezeptorvermittelte Signalwege, wie eine Interaktion mit der Zellmembran (wie beispielsweise mit Lipid rafts), an der Entstehung des mCRP-Effektes in Endothelzellen beteiligt sind. Weitere Untersuchungen sind noch nötig, um den Effekt und seine Bedeutung in der Pathogenese der Arteriosklerose besser zu verstehen. Ansatzpunkte für zukünftige Forschungen sind beispielsweise die Signalkaskade von CRP mit seinen Konfigurationen, die Rezeptoren von CRP und die Herkunft von mCRP in vivo. / Arteriosclerosis and its associated diseases is the disease with the highest mortality worldwide and a high morbidity. Chronic Inflammation has a crucial role in Atherogenesis. Acute-phase proteins, especially C-reactive Protein (CRP) are important predictors for cardiovascular endpoints. Elevated CRP-Levels have been identified by various studies as independent risk factor for cardiovascular endpoints. There is emerging evidence for an active Role of CRP in Atherogenesis surpassing its role as a marker. Oxidized LDL (oxLDL) is well known as risk factor for arteriosclerosis, its uptake into endothelial cells is an important step in Atherogenesis. Acetylated LDL (acLDL) was chosen as model for oxLDL. We could show in FACS-Analysis, that the distinct configurations of CRP, monomeric CRP (mCRP) and pentameric CRP (nCRP) have different effects on the uptake of acLDL in endothelial cells. M-CRP decreases the uptake significantly, nCRP has no effect. This was confirmed in Immunofluorescence, where also a significant decrease in the uptake of acLDL under the influence of mCRP was seen. To further investigate this effect, we examined the role of the putative CRP-Receptors on endothelial cells, CD16 and CD32. In RT-PCR there was no mRNA expressed in the endothial cells, and function-blocking antibodies directed against CD16 and CD32 had no influence on the uptake of acLDL. We conclude, that CD16 and CD32 (with its isoforms a,b and c) are not expressed in endothelial cells and do not take part in the inhibitory effects of mCRP on the uptake of acLDL. We suggest that other receptors and/or non-receptormediated signalpathways, like an interaction with the cell membrane (e.g. lipid rafts) mediate this effect. Further investigations are needed to better understand this effect and its role in Atherogenesis, the signaling cascade of CRP and its configurations, the receptors for CRP and the origin of mCRP in vivo.

Natural Killer (NK) cells are cytotoxic lymphocytes that can recognize and kill virally infected or tumour transformed cells by the secretion of cytolytic granules containing perforin. An individual NK cell can kill several target cells sequentially. Each target cell can trigger NK cell activation via different activating ligands and here we report that the order in which ligands are encountered affects the NK cell response. When NK cells are repeatedly activated via their Fc receptor CD16, with the therapeutic antibody rituximab, perforin secretion decreases with each stimulation. However, perforin secretion is restored to its initial level upon subsequent activation by MICA, which ligates NKG2D. Repeated stimulation of NK cells via MICA also decreases the degranulation capacity of NK cells but, strikingly, this effect cannot be rescued by a subsequent stimulation with rituximab. The strength of perforin secretion is also translated to killing of Daudi target cells, expressing different ligands. When Daudi, opsonised with rituximab is the first target NK cell encounters, the sequential killing of another opsonised rituximab or Daudi, expressing MICA will not be affected. But, when Daudi-MICA is met first, the consecutive killing of Daudi-MICA as well as Daudi-rituximab will be impaired. We found that the mechanism underlying these differential outcomes involves shedding of CD16, which occurs upon NK cell activation through both, CD16 and NKG2D. Shedding of CD16 renders the cells insensitive to further activation via that receptor but they remain competent for further activation through NKG2D. Interestingly, however, we also identified the beneficial role of CD16 shedding for NK cell serial killing. NK cells are more motile on rituximab-coated surfaces than on MICA-coated surfaces and their migration speed decreases upon inhibition of CD16 shedding. Moreover, the inhibition of CD16 shedding also prevents the NK cell detachment from rituximab opsonised Daudi cells. Thus, the shedding of the receptor can serve to augment NK cell motility to move between target cells. Efficient NK cell detachment also correlated with their increased survival. Finally, we report that CD16 is constitutively organised in small, dense nanoclusters and that the ligation with rituximab does not affect their spatial distribution. Despite the shedding of the receptor, leading to less protein molecules at the surface, the area of these clusters remains the same. Together these data suggest that CD16 shedding hinders NK cell cytotoxicity against opsonised targets, but promotes their movements between different targets. Thus, receptor shedding is important for efficient NK cell serial killing. Manipulation of CD16 shedding, perhaps by boosting its recovery, might therefore represent an important target for NK cell-based therapies including treatments with therapeutic antibodies.

Background: Patients with burns are susceptible to organ failure, and there is indirect evidence that leukocytes may contribute to this process. They may change the expression of cell-surface receptors after certain stimuli, for example, the burn. We therefore aimed to assess the changes induced by the burn in the expression of leukocyte cell-surface receptors CD11b, CD14, CD16, and CD62L on the surface of PMNs and monocytes. We also wanted to examine the dynamics of this activation during the first week after the burn, and to relate it to the size of the injury. Methods: Ten patients with burns of andgt;15% (TBSA) were included in the study. Blood samples were collected on arrival and every consecutive morning during the first week. Healthy volunteers acted as controls. Results: PMN CD11b expression was increased. The extent of PMN CD11b expression correlated negatively to the size of the full thickness burn. Monocyte CD14 expression increased initially but there was no relation to the size of the burn. PMN CD16 expression decreased initially during the first days and the decrease was related to burn size. CD62L did not vary depending on the burn in either PMN or monocytes during the first week after the burn. Conclusion: This study showed that specific receptors on the surface of leukocytes (PMN CD11b, monocyte CD14 and PMN CD16) are affected by the burn. Expression of PMN CD11b and CD16 are related to burn size. Burn-induced effects on the expression of PMN receptors, such as PMN CD11b and CD16, may contribute to burn-induced infection susceptibility. / Original Publication: Joakim Johansson, Florence Sjögren, Mikael Bodelsson and Folke Sjöberg, Dynamics of leukocyte receptors after severe burns: An exploratory study, 2011, BURNS, (37), 2, 227-233. http://dx.doi.org/10.1016/j.burns.2010.08.015 Copyright: Elsevier Science B.V., Amsterdam. http://www.elsevier.com/

Cellular adhesion research has recently focused on the small scale at the level of individual receptor-ligand bonds. This trend in research is primarily due to experimental advances which allow such individual bond force measurements. Here, one of these techniques, micromanipulation, has been extended to not only determine the bond force of individual receptor-ligand pairs, but also the intrinsic kinetic rates of the interaction. Using transmembrane (TM ) Fc gamma receptor III (CD16a-TM) and human IgG (hIgG), the dependence of adhesion probability on receptor-ligand expression densities, contract duration and contact area was quantitated. A probabilistic based theoretical formulation was developed and validated that relates the intrinsic molecular kinetic rates of the receptorVligand interaction to the experimentally determined adhesion probability. This theoretical formulation describing individual receptor-ligand kinetics has also allowed direct evaluation of existing biophysical bond strength/kinetics paradigms at the extreme condition of single bonds. A force-displacement model was also developed to quantitate the force exerted on the RBC membrane transducer during the micropipette retraction process and found to be in agreement with previous work. In addition to CD16a-TM, the kinetic rates of CD16a anchored via a glycosyl phosphatidylinositol (GPI) moiety (CD16a-GPI) and the two alleles of CD16b (NA1 and NA2) were determined for human, rabbit, and mouse IgG species. The binding affinity of these CD16 interactions to soluble IgG was also measured by traditional bulk chemistry approaches and compared to those measured via the micromanipulation protocol in which the IgG ligand is membrane bound in the solid phase. These data suggest that the membrane anchor itself can alter CD16 binding properties. This represents the first reported effect of the anchor on an intrinsic receptor property, its kinetic rates and binding affinity. This thesis presents two specific aims or goals. These goals were achieved and reported in this thesis. During the course of this research, I also explored other directions and gathered initial data. These directions were further explored by other researchers but the initial data is also presented here.

CD16 is a physiologically essential Fc and #947; receptor III as either a single- pass transmembrane protein (CD16A) or as a glycosylated phosphatidylinositol (GPI) anchored protein (CD16B) on the surface of immune cells that have been implicated in many autoimmune and immune complex-mediated diseases. Its functions include binding and clearing antibody (IgG) coated foreign pathogens, receptor-mediated phagocytosis, and triggering antibody dependent cellular cytotoxicity. It is well established that these functions depend on protein-protein interaction between CD16 and the Fc domain of IgG. However, the molecular details of CD16-IgG interactions are less well defined, but are essential to developing therapeutic compounds to treat many autoimmune and IC diseases. Stable mammalian cell lines expressing wild-type CD16 isoforms and site-specific mutants, including extracellular soluble fragments of CD16 have been established. Soluble forms of wild type CD16A and these CD16 mutants were expressed in a bacterial pathway in order to amass sufficient quantities for x-ray crystallographic studies. The soluble portions of wild-type CD16A and several site-specific CD16A and CD16B mutants were constructed by PCR amplification and ligation with a pET vector. The proteins were expressed in a prokaryotic pathway, BL21 AI, for 8-10 hours and lysed to obtain inclusion bodies. A hand-held sonicator was used to wash the inclusion bodies, while a Urea solution separated and dissolved the proteins. The target proteins were then refolded by rapid dilution, concentrated with a stir cell, and purified. Wild type sCD16A and four site specific mutants were constructed with good sequencing, while wild type sCD16A, sCD16A F176V, and sCD16A G147D were expressed and refolded to optimal levels. X-ray crystallographic data has been collected from sCD16A F176V as a result of these studies and crystals are currently being grown from wild type sCD16A and sCD16A G147D.

Po pirmosios širdies transplantacijos 1967 metais, ši operacija iš eksperimentinio gydymo tapo šiuolaikiniu, pažangiu sunkių širdies ligų gydymo būdu. Širdis šiuo metu yra trečias pagal dažnumą transplantuojamas organas JAV. UNOS (angl. Unaited Network for Organs Sharing) duomenimis JAV kasmet atliekama 2700 širdies transplantacijos operacijų. Tyrimai rodo, kad pirmuosius metus po operacijos išgyvena apie 85% pacientų, pirmus trejus metus – 75% pacientų. ISHLT (angl. International Society for Heart and Lung Transplantation) registravimo duomenys rodo, kad šiuo metu pasaulyje gyvena apie 50 000 žmonių, turinčių širdies transplantatą [20]. Nepakankamas donorų skaičius skatina mokslininkus ieškoti alternatyvių širdies ligomis sergančių pacientų gydymo būdų. Šiuo metu daug dėmesio skiriama kamieninių ląstelių tyrimams ir galimam jų pritaikymui įvairiom ligom gydyti. Su eksperimentiniais pelių modeliais parodyta, kad kamieninės ląstelės, implantuotos į širdies raumenį, geba diferencijuotis į kardiomiocitus ir kraujagyslių endotelio ląsteles ir atkurti pažeistą raumenį. Taučiau publikuota ir nemažai nesėkmių, susijusių su kamieninių ląstelių terapija, pvz.: neprigyjimas implantuotoje vietoje, nepilna diferencijacija [59]. Žmogaus mezenchiminių kamieninių ląstelių auginimas užtrunka, o gydymo dažnai prireikia tuoj pat [50]. Šios ir daug kitų problemų reikalauja daugybės tyrimų ir eksperimentų, todėl transplantacija kol kas išlieka pagrindiniu gydymo būdu, prailginančiu pacientų... [toliau žr. visą tekstą] / The ame of this work was to evaluate the changes of the expresion of T lymphocyte CD16/56, CD103, CD134 surface markers in the blood of the patients who underwent heart transplantation. For this purpose we collected heparinized blood samples of 21 patients with cardiac transplant and 29 healthy volunteers. 9 patients out of 21 underwent acute cardiac transplant rejection. Blood samples of these patients were tested using flow cytometry 10 days before heart rejection and on the day when rejection was uphold. Our results showed that the expresion of T lymphocyte CD16/56 surface molecule is higher on the rejection day then in controle group. Exspresion of CD103 marker is higher 10 days before rjection than on the rejection day and is lower then in healthy volunteers. Expresion of CD134 marker is higher before transplant rejection and higher then in healthy controles. Monitoring of CD3+CD103+ and CD+CD134+ cells in the blood after heart transplantation could be helpful in prediction of heart transplant rejection.

No description available.

La transplantation rénale est la stratégie de suppléance rénale la plus performante. Le renforcement des thérapeutiques ciblant la réponse cellulaire T (i) a conduit à réévaluer la réponse allogénique humorale et (ii) a souligné deux complications majeures de la pression immunosuppressive : l’infection à cytomégalovirus CMV et le risque de cancer. Dans le travail présenté ici, nous analysons d’abord l’impact histologique de deux de ces facteurs de détérioration de l’allogreffon rénal : l’infection à CMV avant une biopsie sur indication et la pathogénicité des anticorps anti-HLA dirigés contre le donneur, détectés par des techniques d’identification en Single Antigen in situ dans le greffon. Nous montrons ensuite comment les lymphocytes T (LT) γδ Vd2neg font le lien entre CMV et DSA : induits par le CMV, les LT γδ Vd2neg participent aux lésions médiées par les DSA par leur capacité à réaliser une lyse dépendante de l’anticorps (ADCC) impliquant le CD16. En plus de cette nouvelle fonction allogénique indirecte, les LT γδ Vd2neg possèdent une double réactivité anti-CMV et anti-tumoral. Nous présentons ici un modèle où les lymphocytes T γδ Vδ2neg s’activent spécifiquement de façon TCR dépendante par la reconnaissance d’un marqueur d’intégrité épithéliale (EphA2) : ils détournent le mécanisme d’interaction classique d’EphA2 avec ses ligands naturels éphrines A1 et A4 pour s’en faire un signal de costimulation, en s’appuyant sur le contexte de stress pour renforcer son activation. Collectivement, nos résultats contribuent à mieux préciser la bioréactivité et le rôle des LT γδ Vδ2neg en transplantation rénale. Nos données suggèrent que chez l'homme, a fortiori lorsqu’il est immunodéprimé, les LT γδ constituent un compartiment de surveillance lymphoide du stress, capable de censurer la dérégulation des cellules infectées ou transformées et de prendre part à la réponse allogénique par un mécanisme d’ADCC. / Kidney transplant is the most performant strategy for renal replacement therapy. Increasing treatment targetting T cell response has led (i) to reappraise the importance of humoral allogenic response, (ii) to underline two main complications subsequent to immunosuppressive pressure : cytomegalovirus infection and tumorigenesis. Here, we first report the pathological impact of two of these factors on kidney allograft deterioration : CMV infection prior a biopsy for cause and Donor Specific Alloantibodies (DSA) detected within the graft with single antigen flow bead assay. Then we showed that CMV-induced Vδ2neg γδ T cells are a new player and a potentially useful clinical biomarker in antibody-mediated lesions of kidney transplants. By engaging DSA on their Fcγ-receptor CD16, γδ T cells participate in allograft lesions mediated by DSA through antibody-dependent cell cytotoxicity (ADCC). In addition to this new indirect allogenic function, CMV-induced Vδ2neg γδ T cells displayed a dual anti-CMV and anti-tumor reactivity. Finally, we here identified EphA2 as a new stress-regulated antigen targetting by a non Vδ2neg γδ T cell clone, which recognition implies the hijacking of the natural EphA2-ephrin interactions to activation. These data suggest that in humans, a fortiori when immunosuppressed, γδ T cells compose a lymphoid stress-surveillance compartment, capable of recognizing the dysregulated state of infected or transformed cells and to take part to allogenic response through an ADCC mechanism.

Introdução: Os receptores Fc são proteínas de importância crucial no processo saúde-doença. São responsáveis pela ativação de mecanismos efetores e modulam a resposta imune e inflamatória. Têm papel central na patogênese de doenças autoimunes, sepse e doenças neoplásicas. O lúpus, protótipo das doenças autoimunes e a sepse, infecção grave que causa disfunção orgânica, são doenças inflamatórias nas quais o papel dos receptores Fc vêm sendo desvendados. Essas patologias têm alta morbidade e mortalidade, impondo enormes custos para sociedade. A descoberta que a E. coli se liga ao receptor CD16 (FcGamaRIII) para evadir-se do sistema imune, através da ligação com a proteína wzxe presente em sua membrana, torna esse receptor um alvo terapêutico interessante. O CD16 é um FcGamaR com ITAM que classicamente tem função ativadora e gera respostas inflamatórias ao se ligar a imunocomplexos. Porém, na sepse, a ligação direta com a E. coli induz uma ativação ITAMi, que bloqueia a produção de ROS e inibe a fagocitose e a morte desta bactéria. A manipulação dessa ativação inibitória (ITAMi), aparentemente anti-inflamatória, pode ser uma estratégia efetiva para o tratamento de doenças inflamatórias como a sepse e o lúpus. Inicialmente visamos avaliar a importância fisiológica e o papel terapêutico do peptídeo ligante do CD16, em modelo de sepse e em modelo de lúpus induzido por pristane, respectivamente. De maneira similar ao CD16, o CD89 (FcAlfaRI) é capaz de mediar uma sinalização dual, ativatória ou inibitória, que depende da forma como se dá sua ligação às imunoglobulinas e imunocomplexos. Por isso, num segundo momento, averiguamos se o FcAlfaRI (CD89) poderia se ligar à bactérias de maneira direta, na ausência de ligantes cognatos e mediar respostas pro ou anti-inflamatórias, protegendo ou não o hospedeiro. Metodologia: Camundongos C57Bl/6, WT e CD16KO com lúpus induzido por pristane, foram tratados com o peptídeo CYWGGTEGAC(IRG Bioscience,USA). A expressão gênica e protéica de diversas citocinas, assim como genes associados a assinaturas de interferon foram avaliados nos pulmões desses animais. Utilizamos também um modelo de sepse através da injeção intra-peritoneal de E. coli WT e E. coli mutante wzxe -/-, no qual avaliamos mortalidade e produção de citocinas. Realizamos experimentos in vitro com BMM e BMDC murinos, fagócitos humanos e bactérias. A expressão de CD89 e de receptores cognatos foi avaliada através de citometria de fluxo. Empregamos a citometria de fluxo com imagem para análise da fagocitose. Foram realizados também, experimentos in vivo com camundongos WT e transgênicos: CD89tg, CD89R209Ltg CD89tgCD16KO, CD16KO e PCRKO. Comparamos mortalidade, produção de citocinas, quantidade de bactérias e lesão tecidual em modelos de CLP e de pneumonia por administração nasal de S. pneumoniae. Produção de ROS pelos BMM foi avaliada por microscopia confocal e, nos PMN, por quimioluminescência. Imunoprecipitação e immunoblotting foram utilizados para avaliar recrutamento de syk e SHP-1. Utilizamos ELISA para ensaios de ligação de bactérias com CD89 e para quantificar TNF-Alfa, IL-1 e IL-6. Resultados: Camundongos injetados com a bactéria mutante wzxe-/- sobreviveram mais e produziram quantidade menor de citocinas reforçando o papel chave da proteína wzxe, no mecanismo de evasão imune da E. coli. Camundongos WT e CD16KO com lupus induzido por pristane, tratados ou não com peptídeo CYWGGTEGAC, não apresentaram diferenças na expressão gênica nem protéica de citocinas nem em genes associados a assinaturas de interferon em seus pulmões. O CD89 interage diretamente com bactérias gram-positivas e gram-negativas. A interação bactéria-CD89 em macrófagos murinos induz ativação celular, fagocitose e morte bacteriana, que são dependentes da cadeia FcRGama. Essa mesma interação protege contra a mortalidade em dois modelos de sepse (CLP e pneumonia) e é dependente da cadeia FcRGama e indepedente de PCR e IgA anti-bactéria. Conclusões: O CD16 e o CD89 são FcRs com ITAM que apresentam uma dualidade na forma de ativação através do ITAM, que em algumas situações pode ser inibitória (ITAMi). Nessa tese reforçamos o papel chave da proteína wzxe, ligante do CD16, como responsável pela evasão bacteriana da E. coli através de sinalização ITAMi. Por outro lado, falhamos em demostrar diferenças após o tratamento de camundongos com lúpus induzido por pristane usando o peptídeo CYWGGTEGAC. Acreditamos que isso tenha ocorrido devido a dose inadequada do peptídeo ou proteólise por enzimas endógenas do camundongo, assim que o peptídeo é injetado. Novas doses ou a manipulação da estrutura do peptídeo são perspectivas futuras para este projeto. Quanto ao CD89, provamos seu papel extremamente importante na imunidade inata. Esse receptor, à semelhança do CD16, foi capaz de ligar-se diretamente a bactérias, na ausência de opsoninas e ligantes cognatos. O CD89 foi protetor tanto para infecção por gram-positivo quanto por gram-negativo enquanto o CD16 foi protetor apenas em modelo de pneumonia por gram-positivo / Introduction: Fc receptors are proteins of crucial importance in the health-disease process. They are responsible for the activation of effector mechanisms and modulate the immune and inflammatory responses. They play a central role in the pathogenesis of autoimmune diseases, sepsis and neoplastic diseases. Lupus, a prototype of autoimmune diseases and sepsis, a serious infection that causes organ dysfunction, are inflammatory diseases in which the role of Fc receptors has been unraveled. These pathologies have high morbidity and mortality, imposing enormous costs for society. E. coli has been found to bind directly to the FcGammaRIII(CD16) receptor to evade the immune system. This is due to the binding to the wzxe protein present in its membrane, making this receptor an interesting therapeutic target. CD16 is an FcGammaR with ITAM that classically has an activating function and generates inflammatory responses when binding to immunocomplexes. However, in sepsis, direct binding with E. coli induces an ITAMi activation, which blocks ROS production and inhibits phagocytosis and death of this bacterium. The manipulation of this apparently anti-inflammatory inhibitory signaling (ITAMi) may be an effective strategy for the treatment of inflammatory diseases such as sepsis and lupus. Initially we aimed to evaluate the physiological importance and therapeutic role of the CD16 binding peptide, in a sepsis model and pristane-induced lupus model, respectively. Similarly to CD16, CD89 (FcAlphaRI) is capable of mediating dual, activating or inhibitory signaling, which depends on how it binds to immunoglobulins and immunocomplexes. Therefore, we assessed whether FcAlphaRI (CD89) could bind to bacteria directly, in the absence of cognate ligands and mediate pro or anti-inflammatory responses, protecting or not the host. Methods: C57Bl/6 mice, WT and CD16KO with pristane-induced lupus were treated with the peptide CYWGGTEGAC (IRG Bioscience, USA). Gene and protein expression of cytokines, as well as genes associated to interferon signatures were evaluated in the lungs of these animals. We also used a sepsis model through the intra-peritoneal injection of E. coli WT and E. coli mutant wzxe-/-, in which we evaluated mortality and production of cytokines. We performed in vitro experiments with murine BMM and BMDC, human phagocytes and bacteria. Expression of CD89 and cognate receptors was assessed by flow cytometry. Flow cytometry with imaging was employed for phagocytosis analysis. In vivo experiments were also performed on WT and transgenic mice: CD89tg, CD89R209Ltg CD89tgCD16KO, CD16KO and CRPKO. We compared the mortality, cytokine production, amount of bacteria and tissue injury in CLP and pneumonia by nasal administration of S. pneumoniae. ROS production by BMM was evaluated with confocal microscopy and, in PMN, by chemiluminescence. Immunoprecipitation and immunoblotting were used to evaluate recruitment of syk and SHP-1. We used ELISA for binding assays with CD89 and bacteria and quantification of TNF-Aphla, IL-1 and IL-6. Results: Mice injected with wzxe-/- mutant E. coli survived more and produced smaller amounts of cytokines, reinforcing the key role of the wzxe protein in the mechanism of immune evasion of E. coli. WT and CD16KO pristane induced lupus mice, treated or not with the peptide CYWGGTEGAC didn\'t show differences in gene or protein expression of cytokines nor in interferon signature genes in their lungs. The bacterial-CD89 interaction in murine macrophages induces cellular activation, phagocytosis and bacterial death, which are dependent on the FcRGamma chain. This same interaction protects against mortality in two models of sepsis (CLP and pneumonia) and is dependent on the FcRGamma chain and independent of PCR and IgA anti-bacterium. Conclusions: CD16 and CD89 are ITAM-bearing FcRs that present a duality in the form of activation through ITAM, which in some situations may be inhibitory (ITAMi). In this thesis we reinforce the key role of wzxe protein, a CD16 ligand, as responsible for the bacterial evasion of E. coli through ITAMi signaling. On the other hand, we failed to demonstrate differences after treatment of pristane-induced lupus mice using the CYWGGTEGAC peptide. We believe that this was due to inadequate dose of the peptide or proteolysis by endogenous mouse enzymes, so the peptide is injected. New doses or manipulation of the peptide structure are future prospects for this project. As to CD89, we proved the extremely important role of CD89 in innate immunity. That receptor, similarly to CD16, was able to bind directly to bacteria, in the absence of opsonins and cognate ligands. CD89 was protective for both gram-positive and gram-negative infection while the CD16 was protective only in a model of gram-positive pneumonia